Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WASP -- Ignore unavailable to you. Want to Upgrade?

To: Bill on the Hill who wrote (15)	4/19/1999 3:23:00 PM
From: Bill on the Hill	Read Replies (1) \| Respond to of 193

News: biz.yahoo.com Related Quotes WASP 1 5/8 -7/16 delayed 20 mins - disclaimer Monday April 19, 3:03 pm Eastern Time Company Press Release Skin Rejuvenation Midvale, UTAH--(BUSINESS WIRE)--Wasatch Pharmaceutical Inc. (OTC BB:WASP - news) announced its intentions to pursue the skin rejuvenation market along with its medical treatment technology for various common skin disorders. The actual rejuvenation of skin cells was an accidental discovery resulting from the treatment of various skin diseases during the last five years of clinical studies conducted by Wasatch in their own prototype clinics. These studies found that the products and technology developed by Wasatch over the past fifteen years will have broad application in the skin care markets. Future news releases will center on the evaluation of our studies and show how our successes will translate into products ready for marketing to the general public. It became evident in the early stages of research with Acne and Eczema that dramatic changes in the appearance of patient's skin was taking place. In older patients especially, the difference was extremely dramatic. Old and tired looking skin became beautiful, smooth, and younger looking in appearance. The full extent of this skin rejuvenation became apparent usually within eight weeks of treatment with no reported side effects of any kind. There are many products that make claims in the area of skin rejuvenation. What they are actually doing to the skin is not always clear, and the effects are usually very temporary and measured only by hours in the skin's improved appearance. In the case of the Company's products, actual regeneration and rejuvenation of the skin cells appears to take place over a six to eight week period, and is maintained with continued use of the products involved. Marketing of these products should receive broad acceptance with the public for both men and women in the $10 billion skin rejuvenation market. The Company plans to joint venture these products with a major beauty care marketing company to be announced in the future. Wasatch feels confident that superior products, centered around its core technology, will find widespread acceptance by consumers looking for products that really perform as they claim. NOTE: Any statements released by Wasatch Pharmaceutical Inc. that are not strictly historical are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the company's business prospects and performance. These include economic, competitive, governmental, technological and other factors discussed in the company's filings with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709 --------------------------------------------------------------------------------

To: Bill on the Hill who wrote (15)	4/19/1999 8:08:00 PM
From: SteelerStu	Read Replies (1) \| Respond to of 193

WASP -- Business Summary below: BACKGROUND: -- 14 year old company. -- "The products and medical therapies developed by this company represent the most important breakthrough in the field of Dermatology in the last fifty years." -- "Significant successes in the area of skin disease include: Cystic Acne, Eszema, Seborrhea, Contact Dermititis, Molluscum, Follicultis, Acne Rosacea, and less prevalent skin diseases." -- Wasatch is now on line with insurance providers independent of HMO's. Efforts to establish preferred providership status with HMO's is presently being pursued. -- American Institute of Skin Care, Inc, (AISC) is a wholly owned subsidiary of WASP. 3 currently in UTAH to grow to 350 nationwide in 5 years. -- In addition to the clinical products the company will be developing Over-The-Counter products. COMPETITION: -- "Competing products address the symptoms of acne and eczema and not the cause." -- "At this time there is no known competitor who treats the causes of these skin disorders and no competitor can claim a success rate equal to that of the AISC treatments." MARKETING: -- "To carry out our marketing strategies we will concentrate on a strong relationship with insurance health providers, media promotion of the clinics and OTC sales."